目的：系统评价眼用0.01%、0.025%和0.05%阿托品对于近视儿童等效球镜度及眼轴长度的影响。

方法：检索PubMed、Embase、Cochrane Library、Web of Science、中国知网、万方数据库、维普网、中国生物医学文献数据库中从建库至2022-05期间发表的关于0.01%、0.025%和0.05%阿托品进行近视控制的研究。使用Cochrane手册对纳入文献进行偏倚风险评价及质量评价，并使用Revman 5.4软件进行Meta分析，利用STATA12.0软件检测发表偏倚。

结果：共计纳入6篇文献1 239眼，其中5项为随机对照试验，1项为病例对照研究。Meta分析显示，0.025%阿托品对SE及AL的抑制效果好于0.01%阿托品(SE：WMD=-0.15，95%CI：-0.23～-0.06，P<0.001； AL：WMD=0.07，95%CI：0.03～0.10，P<0.001)。0.05%阿托品对SE及AL抑制效果好于0.01%阿托品(SE：WMD=-0.35，95%CI：-0.44～-0.26，P<0.001； AL：WMD=0.16，95%CI：0.12～0.20，P<0.001)。0.05%阿托品对SE及AL增加的抑制效果好于0.025%阿托品(SE：WMD=-0.20，95%CI：-0.28～-0.11，P<0.001； AL：WMD=0.09，95%CI：0.06～0.12，P<0.001)。

结论：0.05%阿托品对SE及AL的控制效果优于0.025%及0.01%阿托品，但长期使用的副作用仍有待进一步观察。

METHODS: PubMed, Embase, Cochrane Library, Web of Science, CNKI, Wanfang Database, VIP and CBM were searched for all publications related to 0.01%, 0.025% and 0.05% atropine to control myopia simultaneously. The publication time is from the database construction to May 2022. The Cochrane handbook was used to evaluate the risk of bias and quality of the included literature, STATA12.0 was used to detect publication bias and Revman5.4 software was used for Meta-analysis.

RESULTS: A total of 6 literatures(1 239 eyes)were included, with 5 randomized controlled trials and 1 case-control study. Meta-analysis results showed that 0.025% atropine had better inhibitory effect on SE and AL than 0.01% atropine(SE: WMD=-0.15, 95%CI: -0.23--0.06, P<0.001; AL: WMD=0.07, 95%CI: 0.03-0.10, P<0.001). The inhibitory effect of 0.05% atropine on SE and AL was better than 0.01% atropine(SE: WMD=-0.35, 95%CI: -0.44--0.26, P<0.001; AL: WMD=0.16, 95%CI: 0.12-0.20, P<0.001). The inhibitory effect of 0.05% atropine on SE and AL increase was better than 0.025% atropine(SE: WMD=-0.20, 95%CI: -0.28--0.11, P<0.001; AL: WMD=0.09, 95%CI: 0.06-0.12, P<0.001).

CONCLUSION: The concentration of 0.05% atropine is superior to 0.01% and 0.025% atropine in the control of SE and AL. However, the side effects of long-term use remain to be observed.